August 16th 2025
Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities and protect quality of life, according to Courtney Moore, APRN, FNP-C, OCN.
Loperamide Plus Budesonide Lessons Diarrhea With Neratinib in HER2+ Breast Cancer
December 9th 2016According to findings from a phase II trial, prophylactic treatment with a combination of loperamide and budesonide reduced the rate of all-grade diarrhea associated with neratinib to 65%, compared with 95.4% observed in the ExteNET trial.
Everolimus/Fulvestrant Combo Improves Survival in HR+ Breast Cancer
December 8th 2016According to phase II trial findings, adding everolimus to fulvestrant significantly improved progression-free survival for postmenopausal patients with metastatic hormone receptor-positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.
The Elephant in the Pink Room: Living With Metastatic Breast Cancer
October 14th 2016When Breast Cancer Awareness Month arrives each October, for many women there is a lot to be thankful for. Research advances have led to less aggressive treatment options and a good prognosis for women with early-stage disease, but for women with metastatic breast cancer (MBC), it is a different story.
Patients With Metastatic Breast Cancer Want Better Communication With Providers
October 14th 2016In 2014, Novartis Oncology commissioned the Harris Poll to conduct the Make Your Dialogue Count survey to identify the emotional needs of patients newly diagnosed with metastatic breast cancer as well as during treatment change.